<DOC>
	<DOCNO>NCT02743429</DOCNO>
	<brief_summary>In trial , monoclonal anti-Disialoganglioside GD2 ( GD2 ) antibody ch14.18/CHO assess treatment patient relapse refractory neuroblastoma . The antibody use single agent apply new treatment schedule associate less side effect .</brief_summary>
	<brief_title>Phase II Study Monoclonal Antibody ch14.18/CHO Continuous Infusion Patients With Primary Refractory Relapsed Neuroblastoma</brief_title>
	<detailed_description>The Treatment ch14.18 antibody demonstrate efficacy patient neuroblastoma . However treatment associate target side effect , i.e . neuropathic pain . This require coadministration intravenous morphine . In clinical Trial evaluate less toxic treatment regimen consist continuous longterm Infusion ( LTI ) ch14.18/CHO administer dose 10 mg/m2/day 10 day ( total dose 100 mg/m2/cycle ) . Patients may receive five 35-day cycle absence sign progression .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Primary refractory relapse neuroblastoma . Tumour burden control conventional therapy ( except patient early minimal bone marrow relapse ) . Measurable and/or evaluable disease follow site ( skeletal lesion , soft tissue lesion , lymph node and/or primary tumour site and/or bone marrow ) measure mIBG scan , CT , MRI and/or immunocytology . Patients life expectancy least 12 week . Progressive disease time inclusion study . ADA positivity due previous treatment antiGD2 antibody ( e.g . ch14.18/Mouse myeloma cell line SP2/0 ( SP2/0 ) , ch14.18/CHO ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ch14.18/CHO</keyword>
	<keyword>neuroblastoma</keyword>
	<keyword>long term infusion</keyword>
</DOC>